Tumor angiogenesis: A pathologist's point of view

Electronic Journal of Oncology

Volumn , Issue 2, 2000, Pages 23-32

  Scoazec, Jean Yves ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CELL RECEPTOR; COLLAGENASE INHIBITOR; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; FUMAGILLIN; NEUROPILIN; PROTEIN TYROSINE KINASE INHIBITOR; THROMBOSPONDIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ACCURACY; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BILE DUCT CARCINOMA; BLOOD VESSEL PARAMETERS; CARCINOGENESIS; CYTOTOXICITY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER TUMOR; MEDICAL SPECIALIST; MICROENVIRONMENT; MOLECULAR MECHANICS; MORPHOLOGY; NONHUMAN; PATHOLOGY; PROGNOSIS; PROTEIN FUNCTION; REVIEW; TUMOR CELL; TUMOR VOLUME;

EID: 3242664194     PISSN: 12928933     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Furcht LT. Critical factors controlling angiogenesis: cell products, cell matrix, and growth factors. Lab Invest 1986;55:505-509.
2. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-447.
3. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
5. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.
6. Mattot V, Pourtier A, Soncin F, Vandenbunder B. La morphogenèse de l'arbre vasculaire. De la compréhension des mécanismes moléculaires aux perspectives thé rapeutiques. Med-Sci 1998;14:437-447.
7. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol 1995;159:113-60.
8. Ortega N, Hutchings H, Plouet J. Signal relays in the VEGF system. Front Biosci 1999;4:D141-52.
9. Ortega N, Jonca F, Vincent S, Favard C, Ruchoux MM, Plouet J. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. Am J Pathol 1997;151:1215-24.
10. Strömblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol 1996;6:462-467.
11. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103:1227-30.
12. Joukov V, Kaipainen A, Jeltsch M, et al. Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol 1997;173:211-5.
13. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9:211-220.
14. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999;13:9-22.
15. Giger RJ, Urquhart ER, Gillespie SK, Levengood DV, Ginty DD, Kolodkin AL. Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron 1998;21:1079-92.
16. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994;54:6504-11.
17. Volpert OV, Stellmach V, Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 1995;36:119-26.
18. Fontanini G, Boldrini L, Calcinai A, et al. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res 1999;5:155-61.
19. Maeshima Y, Colorado PC, Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 2000;275:23745-50.
20. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
21. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
22. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991;22:339-47.
23. Iliopoulos O, Kaelin WG, Jr. The molecular basis of von Hippel-Lindau disease. Mol Med 1997;3:289-93.
24. Chiarugi V, Magnelli L, Gallo O. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. Int J Mol Med 1998;2:715-9.
25. Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol 1998;5:271-8.
26. Toth K, Vaughan MM, Peress NS, Slocum HK, Rustum YM. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 1996;149:853-858.
27. Nakamura S, Muro H, Suzuki S, et al. Immunohistochemical studies on endothelial cell phenotype in hepatocellular carcinoma. Hepatology 1997;26:407-415.
28. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vasc Biol 1997;17:1193-202.
29. Wisse E, De Zangen RB, Charels K, van der Smissen P, McCuskey R.. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology 1985;5:683-692.
30. Scoazec J-Y, Feldmann G. Both endothelial cells and macrophages of the human hepatic sinusoid express CD4, a receptor for the human immunodeficiency virus (HIV). Hepatology 1990;12:505-510.
31. Kawahara N, Ono M, Taguchi K, et al. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 1998;28:1512-7.
32. Dumortier J, Anderson W, Nejjari M, et al. L'organisation de l'architecture vasculaire des tumeurs digestives est gouvernée par les cellules tumorales (résumé). Ann Pathol 1998;18 (suppl):35.
33. Oh SJ, Jeltsch MM, Birkenhager R, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 1997;188:96-109.
34. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999;154:1381-90.
35. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156:361-81.
36. McDonald DM, Foss AJ. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 2001;19:109-20.
37. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-80.
38. Martin L, Green B, Renshaw C, et al. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer 1997;76:1046-54.
39. Schor AM, Pendleton N, Pazouki S, et al. Assessment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J 1998;30:849-56.
40. Vermeulen PB, Verhoeven D, Hubens G, et al. Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol 1995;6:59-64.
41. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32A:2474-84.
42. Lee WJ, Chu JS, Houng SJ, Chung MF, Wang SM, Chen KM. Breast cancer angiogenesis: a quantitative morphologic and Doppler imaging study. Ann Surg Oncol 1995;2:246-51.
43. van Dijke CF, Brasch RC, Roberts TP, et al. Mammary carcinoma model: correlation of macromolecular contrast- enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 1996;198:813-8.
44. Martin L, Holcombe C, Green B, Leinster SJ, Winstanley J. Is a histological section representative of whole tumour vascularity in breast cancer? Br J Cancer 1997;76:40-3.
45. Szabo S, Sandor Z. The diagnostic and prognostic value of tumor angiogenesis. Eur J Surg (Suppl) 1998;582:99-103.
46. Max R, Gerritsen RR, Nooijen PT, et al. Immunohistochemical analysis of integrin alphavbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997;71:320-4.
47. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin alphaVbeta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998;4:2625-2634.
48. Baillie CT, Winslet MC, Bradley NJ. Tumour vasculature - a potential therapeutic target. Br J Cancer 1995;72:257-67.
49. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8.
50. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci USA 1998;95:9064-6.
51. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12.